🎙️ Melinda Knows Best at the AAD! 🌟

We’ve got a special LATEBREAKER episode for you, continuing our coverage from the American Academy of Dermatology in San Diego!

👟💡 Pro Tip: Don't miss Dr. Gooderham’s advice on navigating massive convention centers in style and comfort!

We dive into the highly anticipated Delta 3 study, shedding light on long-term safety and efficacy of Delgocitinib cream for Chronic Hand Eczema.

• Subjects who completed the 16-week treatment period in one of the parent trials DELTA 1 and DELTA 2 were treated with twice daily delgocitinib cream as needed to control their chronic hand eczema for 36 weeks.

Practical Tips for Dermatology Practices 🏥💼

• Adapting treatment plans for chronic hand eczema.
• Benefits of as-needed treatment approaches for better patient outcomes.

Dr. Gooderham’s Conference Adventures 🛫👩‍⚕️👨‍⚕️

• Dr. Gooderham also shares her intriguing encounters from Toronto to San Diego, including a surprise meeting with April Armstrong and an old friend from med school. 🛫

Episode Learning Objectives:

1. Understand the primary and secondary endpoints of the Delta 3 study and its implications for treating chronic hand eczema.
2. Learn about the safety profile of Delgocitinib cream and its significance in long-term treatment plans.
3. Gain insights into real-world application of delgocitinib and patient adherence strategies for topical treatments

Lace up those sneakers, grab a protein bar, and join us for a walk through the latest dermatological advancements! 🥾🍫

🎙️ Melinda Knows Best at the AAD – where expert insights meet real-world application (pun intended)📍📍

Episode supported by an IME Grant from LEO Pharma

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Dermatologist | Toronto

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

References

1. Gooderham M. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial. Presented at: 2024 American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca